$REGN
REGENERON PHARMACEUTICALS, INC.

2020 Q4 Form 10-K Financial Statement

#000180422021000008 Filed on February 08, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 2019 Q4
Revenue $2.423B $8.497B $1.864B
YoY Change 30.02% 29.58% -3.34%
Cost Of Revenue $353.1M $1.120B $223.9M
YoY Change 57.7% 178.03% 91.04%
Gross Profit $2.070B $7.377B $1.946B
YoY Change 6.38% 19.86% 7.46%
Gross Profit Margin 85.43% 86.82% 104.41%
Selling, General & Admin $303.5M $1.346B $586.8M
YoY Change -48.28% 0.31% 19.44%
% of Gross Profit 14.66% 18.25% 30.16%
Research & Development $744.5M $2.735B $683.1M
YoY Change 8.99% 11.63% 12.67%
% of Gross Profit 35.97% 37.07% 35.11%
Depreciation & Amortization $61.70M $235.9M $54.30M
YoY Change 13.63% 12.17% 26.87%
% of Gross Profit 2.98% 3.2% 2.79%
Operating Expenses $902.8M $4.081B $1.270B
YoY Change -28.91% 7.62% 16.24%
Operating Profit $1.167B $3.577B $675.7M
YoY Change 72.71% 61.85% -5.9%
Interest Expense $47.40M $56.90M $53.20M
YoY Change -10.9% 88.41% -828.77%
% of Operating Profit 4.06% 1.59% 7.87%
Other Income/Expense, Net $10.20M $233.8M $160.9M
YoY Change -93.66% 6.61% -566.38%
Pretax Income $1.225B $3.810B $889.8M
YoY Change 37.63% 56.86% 31.59%
Income Tax $75.40M $297.2M $97.80M
% Of Pretax Income 6.16% 7.8% 10.99%
Net Earnings $1.149B $3.513B $792.0M
YoY Change 45.1% 66.05% -3.46%
Net Earnings / Revenue 47.43% 41.35% 42.5%
Basic Earnings Per Share $10.90 $32.65 $7.25
Diluted Earnings Per Share $10.24 $30.52 $6.93
COMMON SHARES
Basic Shares Outstanding 107.6M shares
Diluted Shares Outstanding 115.1M shares

Balance Sheet

Concept 2020 Q4 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.587B $3.587B $3.214B
YoY Change 11.61% 11.61% 14.38%
Cash & Equivalents $2.194B $2.194B $1.618B
Short-Term Investments $1.393B $1.393B $1.597B
Other Short-Term Assets $592.0M $592.0M $788.0M
YoY Change -24.87% -24.87% 37.76%
Inventory $1.917B $1.486B $1.416B
Prepaid Expenses
Receivables $4.115B $4.115B $2.100B
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.779B $9.779B $7.689B
YoY Change 27.18% 27.18% 19.26%
LONG-TERM ASSETS
Property, Plant & Equipment $3.222B $3.222B $2.890B
YoY Change 11.46% 11.49% 12.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.195B $3.195B $3.312B
YoY Change -3.53% -3.53% 83.9%
Other Assets $168.1M $968.0M $144.7M
YoY Change 16.17% 6.02% 13.58%
Total Long-Term Assets $7.384B $7.384B $7.116B
YoY Change 3.77% 3.77% 34.6%
TOTAL ASSETS
Total Short-Term Assets $9.779B $9.779B $7.689B
Total Long-Term Assets $7.384B $7.384B $7.116B
Total Assets $17.16B $17.16B $14.81B
YoY Change 15.93% 15.93% 26.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $475.5M $476.0M $418.1M
YoY Change 13.73% 13.88% 91.61%
Accrued Expenses $1.522B $1.502B $1.087B
YoY Change 40.02% 44.84% 40.8%
Deferred Revenue $577.7M $591.7M
YoY Change -2.37% 30.76%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.697B $2.697B $2.097B
YoY Change 28.66% 28.61% 45.31%
LONG-TERM LIABILITIES
Long-Term Debt $1.979B $2.696B $0.00
YoY Change 277.59% -100.0%
Other Long-Term Liabilities $687.1M $745.0M $317.7M
YoY Change 116.27% -17.68% -12.16%
Total Long-Term Liabilities $2.666B $3.441B $317.7M
YoY Change 739.03% 112.54% -12.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.697B $2.697B $2.097B
Total Long-Term Liabilities $2.666B $3.441B $317.7M
Total Liabilities $6.138B $6.138B $3.716B
YoY Change 65.2% 65.18% 24.8%
SHAREHOLDERS EQUITY
Retained Earnings $10.89B $7.380B
YoY Change 47.61% 40.45%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.613B $739.9M
YoY Change 793.81% 86.65%
Treasury Stock Shares 16.43M shares 4.860M shares
Shareholders Equity $11.03B $11.03B $11.09B
YoY Change
Total Liabilities & Shareholders Equity $17.16B $17.16B $14.81B
YoY Change 15.93% 15.93% 26.17%

Cashflow Statement

Concept 2020 Q4 2020 2019 Q4
OPERATING ACTIVITIES
Net Income $1.149B $3.513B $792.0M
YoY Change 45.1% 66.05% -3.46%
Depreciation, Depletion And Amortization $61.70M $235.9M $54.30M
YoY Change 13.63% 12.17% 26.87%
Cash From Operating Activities $1.231B $2.618B $787.4M
YoY Change 56.34% 7.74% 8.04%
INVESTING ACTIVITIES
Capital Expenditures -$161.4M -$614.6M -$139.0M
YoY Change 16.12% 43.06% 62.57%
Acquisitions
YoY Change
Other Investing Activities -$143.6M $0.00 -$69.70M
YoY Change 106.03% -61.36%
Cash From Investing Activities -$305.0M -$70.60M -$208.7M
YoY Change 46.14% -96.52% -21.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.272B
YoY Change 5003.9%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -305.3M -$1.971B -345.7M
YoY Change -11.69% 681.63% 316.51%
NET CHANGE
Cash From Operating Activities 1.231B $2.618B 787.4M
Cash From Investing Activities -305.0M -$70.60M -208.7M
Cash From Financing Activities -305.3M -$1.971B -345.7M
Net Change In Cash 620.7M $577.0M 233.0M
YoY Change 166.39% 284.41% -38.67%
FREE CASH FLOW
Cash From Operating Activities $1.231B $2.618B $787.4M
Capital Expenditures -$161.4M -$614.6M -$139.0M
Free Cash Flow $1.392B $3.233B $926.4M
YoY Change 50.3% 13.05% 13.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0000872589
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
0-19034
CY2020 dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NY
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3444607
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
777 Old Saw Mill River Road
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Tarrytown
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10591-6707
CY2020 dei City Area Code
CityAreaCode
914
CY2020 dei Local Phone Number
LocalPhoneNumber
847-7000
CY2020 dei Security12b Title
Security12bTitle
Common Stock - par value $.001 per share
CY2020 dei Trading Symbol
TradingSymbol
REGN
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
63344000000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2193700000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1617800000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1393300000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1596500000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3111500000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2100000000.0 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1916600000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1415500000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
160800000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
273700000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
9779100000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
7689100000 USD
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3135600000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3256800000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3221600000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2890400000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
858900000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
824200000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
168100000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
144700000 USD
CY2020Q4 us-gaap Assets
Assets
17163300000 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
4860123 shares
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6613300000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
739900000 USD
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
16431520 shares
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6716200000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4428600000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
10893000000.0 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
7379800000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
29300000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21100000 USD
CY2019Q4 us-gaap Assets
Assets
14805200000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
475500000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
418100000 USD
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1521800000 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1211400000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
122400000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
85000000.0 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2697400000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2096600000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1978500000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
717200000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
713900000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
6138000000.0 USD
CY2019Q4 us-gaap Liabilities
Liabilities
3715500000 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11025300000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11089700000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17163300000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14805200000 USD
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8497100000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6557600000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5145600000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2735000000.0 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2450000000.0 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1468800000 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1346000000.0 USD
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1341900000 USD
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1127200000 USD
CY2020 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
280400000 USD
CY2019 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
209200000 USD
CY2018 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
402300000 USD
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
4920500000 USD
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
4347800000 USD
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
2611200000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
3576600000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
2209800000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
2534400000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
290700000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
249500000 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
47300000 USD
CY2020 us-gaap Interest Expense
InterestExpense
56900000 USD
CY2019 us-gaap Interest Expense
InterestExpense
30200000 USD
CY2018 us-gaap Interest Expense
InterestExpense
28200000 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
233800000 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
219300000 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19100000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3810400000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2429100000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2553500000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
297200000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
313300000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
109100000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
3513200000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
2115800000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
2444400000 USD
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
32.65
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
19.38
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
22.65
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
30.52
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
18.46
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
21.29
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107600000 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109200000 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107900000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115100000 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114600000 shares
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114800000 shares
CY2020 us-gaap Net Income Loss
NetIncomeLoss
3513200000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
2115800000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
2444400000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9100000 USD
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
35900000 USD
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000000.0 USD
CY2020 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-900000 USD
CY2019 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-2500000 USD
CY2018 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
700000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3521400000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2149200000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2438100000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
6144100000 USD
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
114200000 USD
CY2018 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
187200000 USD
CY2018 regn Stock Issued Distributed During Period Value Employee Benefit Plan
StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
26900000 USD
CY2018 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
80200000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
444800000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
2444400000 USD
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-6300000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
8757300000 USD
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
213200000 USD
CY2019 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
188000000.0 USD
CY2019 regn Stock Issued Distributed During Period Value Employee Benefit Plan
StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
38100000 USD
CY2019 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
356700000 USD
CY2019 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
0 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
466900000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
2115800000 USD
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
33400000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11089700000 USD
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2576400000 USD
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
768900000 USD
CY2020 regn Stock Issued Distributed During Period Value Employee Benefit Plan
StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
44700000 USD
CY2020 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
5880900000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
442900000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
3513200000 USD
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8200000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11025300000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
3513200000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
2115800000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
2444400000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
235900000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
210300000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
148200000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
432000000.0 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
464300000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
427400000 USD
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
135000000.0 USD
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
29300000 USD
CY2018 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-12100000 USD
CY2020 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-75600000 USD
CY2019 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
130600000 USD
CY2018 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
140000000.0 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1356100000 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
523700000 USD
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
236400000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
529400000 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
335500000 USD
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
387900000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-114900000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
79800000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
88100000 USD
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
148100000 USD
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
139500000 USD
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-43400000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
118900000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
599000000.0 USD
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
58800000 USD
CY2020 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-895100000 USD
CY2019 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
314200000 USD
CY2018 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-249300000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2618100000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2430000000.0 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2195100000 USD
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3241000000.0 USD
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3202400000 USD
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1845500000 USD
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3785000000.0 USD
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1604200000 USD
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
775600000 USD
CY2020 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
614600000 USD
CY2019 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
429600000 USD
CY2018 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
383100000 USD
CY2020 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 USD
CY2019 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 USD
CY2018 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
10000000.0 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70600000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2027800000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1463000000.0 USD
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1981900000 USD
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2020 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1500000000.0 USD
CY2019 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 USD
CY2018 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 USD
CY2020 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1500000000.0 USD
CY2019 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0 USD
CY2018 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2575200000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
211800000 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
114500000 USD
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
680800000 USD
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
188000000.0 USD
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
187200000 USD
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5846800000 USD
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
275900000 USD
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4400000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1970500000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-252100000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-77100000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
577000000.0 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
150100000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
655000000.0 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1630300000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1480200000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
825200000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2207300000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1630300000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1480200000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
23200000 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
25000000.0 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
22300000 USD
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
188100000 USD
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
342300000 USD
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
205600000 USD
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1211400000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
85000000.0 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6557600000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5145600000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2450000000.0 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1468800000 USD
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1341900000 USD
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1127200000 USD
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
402800000 USD
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
237500000 USD
CY2019 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
209200000 USD
CY2018 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
402300000 USD
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
4347800000 USD
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
2611200000 USD
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
139500000 USD
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-43400000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
599000000.0 USD
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
58800000 USD
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our consolidated </span></div>financial statements as of and for the year ended December 31, 2020; however, actual results could differ from those estimates and there may be changes to our estimates in future periods.
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain investments, and accounts receivable. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties. </span></div>Concentrations of credit risk with respect to accounts receivable are significant. The Company has a concentration of credit risk associated with the receivables due from its collaborators Bayer, Sanofi, and Teva. The Company is also subject to credit risk with accounts receivable from its product sales to its customers.
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
CY2020 regn Up Front And Development Milestone Revenue Recognized
UpFrontAndDevelopmentMilestoneRevenueRecognized
276700000 USD
CY2019 regn Up Front And Development Milestone Revenue Recognized
UpFrontAndDevelopmentMilestoneRevenueRecognized
207200000 USD
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
85300000 USD
CY2018 us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
478900000 USD
CY2018 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
472800000 USD
CY2018Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
91400000 USD
CY2019 us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
727900000 USD
CY2019 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
663200000 USD
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
156100000 USD
CY2020 us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
1136900000 USD
CY2020 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
968800000 USD
CY2020Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
324200000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
3649200000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
40100000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
200000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
3689100000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
4206300000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28500000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
300000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4234500000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1393300000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1596500000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
2295800000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
2638000000.0 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
3689100000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4234500000 USD
CY2020 regn Marketable Securities Realized Gain
MarketableSecuritiesRealizedGain
29000000.0 USD
CY2019 regn Marketable Securities Realized Gain
MarketableSecuritiesRealizedGain
0 USD
CY2018 regn Marketable Securities Realized Gain
MarketableSecuritiesRealizedGain
0 USD
CY2018 regn Marketable Securities Realized Loss
MarketableSecuritiesRealizedLoss
0 USD
CY2020 regn Marketable Securities Realized Loss
MarketableSecuritiesRealizedLoss
0 USD
CY2019 regn Marketable Securities Realized Loss
MarketableSecuritiesRealizedLoss
0 USD
CY2020 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
196000000.0 USD
CY2019 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
118300000 USD
CY2018 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-41900000 USD
CY2020Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
59200000 USD
CY2019Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
55600000 USD
CY2020Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1958000000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
459400000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
216300000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
904600000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
727700000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
121700000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
70600000 USD
CY2020Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
430900000 USD
CY2019Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
400900000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1916600000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1415500000 USD
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
39200000 USD
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
73800000 USD
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
12500000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
4352700000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
3812800000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1131100000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
922400000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3221600000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2890400000 USD
CY2020 regn Depreciation Depletion And Amortization Excluding Intangible Assets
DepreciationDepletionAndAmortizationExcludingIntangibleAssets
230800000 USD
CY2019 regn Depreciation Depletion And Amortization Excluding Intangible Assets
DepreciationDepletionAndAmortizationExcludingIntangibleAssets
205200000 USD
CY2018 regn Depreciation Depletion And Amortization Excluding Intangible Assets
DepreciationDepletionAndAmortizationExcludingIntangibleAssets
144100000 USD
CY2017Q1 us-gaap Lessee Finance Lease Renewal Term1
LesseeFinanceLeaseRenewalTerm1
P5Y
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
465800000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
344400000 USD
CY2020Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
283000000.0 USD
CY2019Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
142700000 USD
CY2020Q4 regn Accrued Sales Related Charges Deductions And Royalties
AccruedSalesRelatedChargesDeductionsAndRoyalties
423900000 USD
CY2019Q4 regn Accrued Sales Related Charges Deductions And Royalties
AccruedSalesRelatedChargesDeductionsAndRoyalties
249000000.0 USD
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
19500000 USD
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
49400000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
329600000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
425900000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1521800000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1211400000 USD
CY2017Q1 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P5Y
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
645700000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
660100000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
717200000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
713900000 USD
CY2020Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
90500000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
76100000 USD
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
14400000 USD
CY2019 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
14400000 USD
CY2020 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
15700000 USD
CY2019 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
27600000 USD
CY2020 regn Finance Lease Cost
FinanceLeaseCost
30100000 USD
CY2019 regn Finance Lease Cost
FinanceLeaseCost
42000000.0 USD
CY2020 regn Finance Lease Remaining Lease Term
FinanceLeaseRemainingLeaseTerm
P1Y2M1D
CY2019 regn Finance Lease Remaining Lease Term
FinanceLeaseRemainingLeaseTerm
P2Y2M1D
CY2020Q4 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.0166
CY2019Q4 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.0305
CY2020Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
12100000 USD
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
723100000 USD
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0 USD
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0 USD
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0 USD
CY2020Q4 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2020Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
735200000 USD
CY2020Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
15100000 USD
CY2020Q4 regn Lessee Finance Lease Liability Debt Financing Costs
LesseeFinanceLeaseLiabilityDebtFinancingCosts
2900000 USD
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
717200000 USD
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
44700000 USD
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
38100000 USD
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
27000000.0 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
2442300000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
2011200000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
2151700000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1368100000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
417900000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
401800000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3810400000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2429100000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2553500000 USD
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
199000000.0 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
444600000 USD
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
223700000 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1200000 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1900000 USD
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4800000 USD
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
21400000 USD
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-2600000 USD
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
20600000 USD
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
221600000 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
443900000 USD
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
249100000 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
109000000.0 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-132000000.0 USD
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
687600000 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2000000.0 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1700000 USD
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1900000 USD
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-31400000 USD
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
3100000 USD
CY2018 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-825700000 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
75600000 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-130600000 USD
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-140000000.0 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
297200000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
313300000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
109100000 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.076
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.025
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.025
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.028
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.046
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.026
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.018
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.010
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.019
CY2020 regn Effective Income Tax Rate Reconciliation Sale Of Non Inventory Related Assets Between Foreign Subsidiaries Percent
EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent
-0.008
CY2019 regn Effective Income Tax Rate Reconciliation Sale Of Non Inventory Related Assets Between Foreign Subsidiaries Percent
EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent
0
CY2018 regn Effective Income Tax Rate Reconciliation Sale Of Non Inventory Related Assets Between Foreign Subsidiaries Percent
EffectiveIncomeTaxRateReconciliationSaleOfNonInventoryRelatedAssetsBetweenForeignSubsidiariesPercent
-0.063
CY2020 regn Effective Income Tax Rate Reconciliation Deduction Foreign Intangible Income Percent
EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent
0
CY2019 regn Effective Income Tax Rate Reconciliation Deduction Foreign Intangible Income Percent
EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent
0.016
CY2018 regn Effective Income Tax Rate Reconciliation Deduction Foreign Intangible Income Percent
EffectiveIncomeTaxRateReconciliationDeductionForeignIntangibleIncomePercent
0.010
CY2020 us-gaap Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit
EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit
0.005
CY2019 us-gaap Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit
EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit
0.007
CY2018 us-gaap Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit
EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.027
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.007
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.009
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.003
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.078
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.129
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.043
CY2018 us-gaap Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit
TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
-68000000.0 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
436600000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
519700000 USD
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
140500000 USD
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
192000000.0 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
139800000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
75900000 USD
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
44600000 USD
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
22000000.0 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
761500000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
809600000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7000000.0 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
761500000 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
802600000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
42800000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
11200000 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
718700000 USD
CY2020 regn Unrecognized Tax Benefits Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations
27600000 USD
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
791400000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
267000000.0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
210800000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
189500000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
210800000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
189500000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
146200000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
76600000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
37900000 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
51400000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
7200000 USD
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
7200000 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
5600000 USD
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107600000 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109200000 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107900000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115100000 shares
CY2019 regn Unrecognized Tax Benefits Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations
9400000 USD
CY2018 regn Unrecognized Tax Benefits Decrease Resulting From Settlements With Taxing Authorities And Reduction Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsDecreaseResultingFromSettlementsWithTaxingAuthoritiesAndReductionResultingFromLapseOfApplicableStatuteOfLimitations
13700000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
267000000.0 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
210800000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
189500000 USD
CY2020Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
9600000 USD
CY2019Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
100000000.0 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
3513200000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
2115800000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
2444400000 USD
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114600000 shares
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114800000 shares
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
32.65
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
19.38
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
22.65
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
30.52
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
18.46
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
21.29
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2193700000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1617800000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1467700000 USD
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
13600000 USD
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
12500000 USD
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
12500000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2207300000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1630300000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1480200000 USD
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
83600000 USD
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
133700000 USD
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
54500000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1828200000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1952000000.0 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2294000000.0 USD
CY2020Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2422900000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
1128100000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
1295600000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
1240900000 USD
CY2020Q4 us-gaap Costs And Expenses
CostsAndExpenses
1255900000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
624600000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
897300000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
842100000 USD
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
1149200000 USD
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.69
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.19
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.98
CY2020Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.90
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.43
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.61
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.39
CY2020Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
10.24
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1372600000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1577800000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1743700000 USD
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1863500000 USD
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
892600000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
1262200000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
1005200000 USD
CY2019Q4 us-gaap Costs And Expenses
CostsAndExpenses
1187800000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
461100000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
193100000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
669600000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
792000000.0 USD
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.23
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.77
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.12
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.25
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.99
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.68
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.86
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.93

Files In Submission

Name View Source Status
0001804220-21-000008-index-headers.html Edgar Link pending
0001804220-21-000008-index.html Edgar Link pending
0001804220-21-000008.txt Edgar Link pending
0001804220-21-000008-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image1a.jpg Edgar Link pending
image2a.jpg Edgar Link pending
image_01.jpg Edgar Link pending
image_21a.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R100.htm Edgar Link pending
R101.htm Edgar Link pending
R102.htm Edgar Link pending
R103.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
regn-20201231.htm Edgar Link pending
regn-20201231.xsd Edgar Link pending
regn-20201231_cal.xml Edgar Link unprocessable
regn-20201231_def.xml Edgar Link unprocessable
regn-20201231_g1.jpg Edgar Link pending
regn-20201231_htm.xml Edgar Link completed
regn-20201231_lab.xml Edgar Link unprocessable
regn-20201231_pre.xml Edgar Link unprocessable
regn-ex_1031x12312020x10k.htm Edgar Link pending
regn-ex_1032x12312020x10k.htm Edgar Link pending
regn-ex_1033x12312020x10k.htm Edgar Link pending
regn-ex_10341x12312020x10k.htm Edgar Link pending
regn-ex_10342x12312020x10k.htm Edgar Link pending
regn-ex_1034x12312020x10k.htm Edgar Link pending
regn-ex_1035x12312020x10k.htm Edgar Link pending
regn-ex_1036x12312020x10k.htm Edgar Link pending
regn-ex_1037x12312020x10k.htm Edgar Link pending
regn-ex_211x12312020x10k.htm Edgar Link pending
regn-ex_231x12312020x10k.htm Edgar Link pending
regn-ex_311x12312020x10k.htm Edgar Link pending
regn-ex_312x12312020x10k.htm Edgar Link pending
regn-ex_32x12312020x10k.htm Edgar Link pending
regn_exx1034-12312020x10k.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending